+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
All Ages
All Genders
ID05564377

Targeted Combination Therapy Based on Genetic Testing for Patients With Advanced Solid Tumors in the ComboMATCH Screening Trial

Led by National Cancer Institute (NCI) · Updated on 2026-11-02

2900

Participants Needed

484

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating targeted cancer treatments directed by genetic testing for patients with locally advanced or advanced solid tumors. This ComboMATCH patient screening trial is designed to match patients with specific genetic mutations in their tumor cells to investigational combination therapies. Patients included have tumors that have spread or progressed after standard treatments, or have no standard treatment proven to extend survival. The study aims to improve treatment planning by using genetic information to assign therapies. Participants undergo tumor mutational screening using previously collected tumor samples. Eligible patients aged 18 and older with biopsiable disease may have a new biopsy before starting treatment. Those with relevant mutations are assigned to one of 20 treatment subprotocols involving various drug combinations and regimens, including oral, intravenous, and intramuscular administration. Treatments are given in repeated 28-day cycles, continuing without disease progression or unacceptable toxicity. The trial includes multiple arms and cohorts tailored to specific genetic alterations and cancer types, with some allowing crossover if disease progresses. Throughout the study, participants have tumor biopsies, blood collections, imaging tests such as CT, MRI, PET scans, and cardiac assessments like echocardiograms or MUGA scans. Bone marrow aspirations or biopsies, bone scans, and brain imaging may also be performed as clinically indicated. Researchers measure patient enrollment and treatment assignment, as well as positive treatment outcomes in defined molecular cohorts. The trial may last up to 8 years, with ongoing monitoring and optional additional biopsies at disease progression to assess treatment effects and safety.

CONDITIONS

Brief Title

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here